In this article, we will discuss Anlotinib (Background-9). So, let’s get started.
Another study revealed that anlotinib binds
to the ATP-binding pocket of VEGFR2 tyrosine kinase and inhibits VEGFR2 with high selectivity (IC50 < 1 nmol/L), thereby inhibiting VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVECs). Moreover, anlotinib suppressed HUVEC migration, tube formation, and
microvessel growth in vitro and reduced vascular density in vivo. Anlotinib had broader and better antitumor efficacy
than did sunitinib in vivo. In cell lines expressing mutated FGFR2 protein, anlotinib decreased the number of cells. Nevertheless, similar to that of other oral RTK inhibitors, the combined treatment of anlotinib with carboplatin and paclitaxel did not appear to be more efficacious than anlotinib alone.